文献速递糖尿病骨质疏松与钙磷/甲状旁腺

1型糖尿病儿童和青少年血清硬骨素和Dickkopf-1(DKK-1)水平升高

High Sclerostin and Dickkopf-1 (DKK-1) Serum Levels in Children and Adolescents With Type 1 Diabetes Mellitus.
PubMed 文献 · J Clin Endocrinol Metab · 2017-01-01

这项横断面研究在临床研究中心纳入106例1型糖尿病儿童和青少年(12.2±4岁,其中66例每日多次注射胰岛素、40例持续皮下胰岛素输注)及80名对照,发现糖尿病患者的硬骨素和DKK-1血清水平显著高于对照,且骨传导时间与振幅依赖声速z评分较低;持续皮下胰岛素输注较每日多次注射改善血糖控制并与更高的BMI-SDS和骨传导时间z评分相关。

要点

  • 1型糖尿病患儿硬骨素和DKK-1血清水平显著高于对照。
  • 每日多次注射胰岛素患者的硬骨素和DKK-1升高较持续皮下胰岛素输注患者更明显。
  • 持续皮下胰岛素输注改善血糖控制并与更高骨传导时间z评分相关。

核心结论

  • 研究强调1型糖尿病儿童存在高血清DKK-1和硬骨素水平及其与血糖控制不佳的关系,以及持续皮下胰岛素输注对改善血糖控制和骨健康的作用。

研究设计与样本

  • 横断面研究,在临床研究中心开展,纳入106例1型糖尿病受试者(12.2±4岁,其中66例每日多次注射胰岛素、40例持续皮下胰岛素输注)和80名对照。

主要发现

  • 糖尿病患者的平均骨传导时间(BTT)和振幅依赖声速(AD-SoS)z评分低于对照。
  • 糖尿病患者DKK-1为3593±1172 pg/mL vs 对照2652±689 pg/mL(P < 0.006),硬骨素为29.45±12.32 vs 对照22.53±8.29(P < 0.001)。
  • 每日多次注射胰岛素患者的DKK-1和硬骨素升高较持续皮下胰岛素输注患者更明显。
  • 持续皮下胰岛素输注患者血糖控制较每日多次注射患者改善(P < 0.001),并与显著更高的BMI-SDS(P < 0.002)和BTT z评分(P < 0.02)相关。
  • 以DKK-1和硬骨素为因变量、校正年龄后的多元线性回归显示,糖化血红蛋白、血糖、25(OH)维生素D、骨钙素、甲状旁腺激素、糖尿病病程、BMI-SDS和AD-SoS z评分是最重要的预测因素(P < 0.0001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Childhood type 1 diabetes mellitus (T1DM) is associated with decreased bone mass. Sclerostin and dickkopf-1 (DKK-1) are Wnt inhibitors that regulate bone formation. OBJECTIVE: To evaluate sclerostin and DKK-1 levels in T1DM children and to analyze the influence of glycemic control on bone health. DESIGN AND SETTING: Cross-sectional study conducted at a clinical research center. PARTICIPANTS: One hundred and six T1DM subjects (12.2 ± 4 years), 66 on multiple daily injections (MDIs) and 40 on continuous subcutaneous infusion of insulin (CSII), and 80 controls. RESULTS: The average bone transmission time (BTT) and amplitude-dependent speed of sound (AD-SoS) z scores were lower in patients with diabetes than in controls. Significantly increased DKK-1 (3593 ± 1172 vs 2652 ± 689 pg/mL; P < 0.006) and sclerostin (29.45 ± 12.32 vs 22.53 ± 8.29; P < 0.001) levels were found in patients with diabetes with respect to controls, particularly in patients on MDI compared with ones on CSII. Glycemic control was improved in CSII patients compared with MDI ones (P < 0.001) and was also associated with significantly higher BMI-SDS (P < 0.002) and BTT z scores (P < 0.02). With adjustment for age, multiple linear regression analysis of DKK-1 and sclerostin as dependent variables showed that levels of glycated hemoglobin, glucose, 25(OH) vitamin D, osteocalcin, and parathyroid hormone; years of diabetes; and BMI-SDS and AD-SoS z score were the most important predictors (P < 0.0001). CONCLUSIONS: Our study highlighted (1) the high serum levels of DKK-1 and sclerostin in T1DM children and their relationship with altered glycemic control and (2) the effect of CSII on improvement of glycemic control and bone health in T1DM children.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Faienza MF, Ventura A, Delvecchio M, et al. High Sclerostin and Dickkopf-1 (DKK-1) Serum Levels in Children and Adolescents With Type 1 Diabetes Mellitus. J Clin Endocrinol Metab. 2017. PMID: 28388723. doi:10.1210/jc.2016-2371

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。